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1561-5413/Copyright ª 2015, Hong KoAbstract Background: Weight gain is common amongst patients who start peritoneal dialysis
(PD). However, the prevalence, risk factors, and long-term implications of body weight gain in
new PD patients have not been explored.
Methods: We studied 444 consecutive new PD patients. Body weight at the time of initiation of
PD and 1 year later, and related clinical factors, were reviewed. Patients were followed for
60.9  32.8 months for survival analysis.
Results: The mean weight change after 1 year of PD was 1.34  3.27 kg; 109 patients (24.6%)
had weight gain > 3 kg. Patients without any peritonitis episodes during the 1st year of PD had
significantly more weight gain than those who had peritonitis (1.58  3.17 vs. 0.16  3.56 kg,
p Z 0.001). There were no significant correlations between body weight change and glucose
load, peritoneal transport characteristics, dialysis adequacy index, or baseline residual renal
function. For patients with weight loss > 0.5 kg, weight change within 0.5 kg, weight gain >
0.5e3.0 kg, and weight gain > 3 kg, the patient survival rates at 60 months were 45.0%,
54.8%, 54.0%, and 52.9%, respectively (p Z 0.213), while technique survival were 28.1%,
40.3%, 40.8%, and 36.7%, respectively (p Z 0.03).
Conclusion: Weight gain is common among Chinese patients during the 1st year of PD but is not
associated with any adverse clinical outcome. In contrast, weight loss during the 1st year of PD
is common amongst PD patients who have peritonitis, and is associated with worse technique
survival subsequently.
背景: 在剛開始腹膜透析(PD)的病人間，體重增加是常見的現象，然而相關的盛行率、危險因
子、及對長期預後的影響至今仍然未明。of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin,
.hk (C.-C. Szeto).
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Weight change after PD 29方法: 研究對象為連續的 444 位剛開始 PD 的病人，我們對其基線及 1 年後體重、及相關的臨床
因素作出分析，存活分析的追蹤期為 60.9  32.8 個月。
結果: 經過第 1年 PD後，平均體重變化為 1.34  3.27 kg，其中 109人 (24.6%)增幅 > 3 kg。相
比於第 1年內曾發生腹膜炎者，非腹膜炎患者的體重增幅較大 (1.58  3.17 vs. 0.16  3.56 kg，
p Z 0.001)。體重變化與以下因素無明顯相關性：葡萄糖負荷、腹膜運輸特徵、透析適量指數、
或基線殘餘腎功能。對於體重下降 > 0.5 kg、體重變化  0.5 kg、體重增加 > 0.5 至 3.0 kg、
及體重增加 > 3.0 kg 者，60 個月的病人存活率分別為 45.0%、54.8%、54.0%、及 52.9%
(p Z 0.213)；技術有效率則分別為 28.1%、40.3%、40.8%、及 36.7% (p Z 0.03)。
結論: 對於剛開始 PD的華裔病人，第 1年內的體重增加是常見現象，但不會引起任何不良臨床後
果；相反，對於第 1 年內曾發生腹膜炎者，體重下降頗為常見，這類病人其後較多發生技術失效
的問題。Introduction
Obesity and overweight are highly prevalent in the general
population. In addition to being a social stigma and being
unsightly, obesity represents an important risk factor of
type 2 diabetes mellitus, hypertension, and cardiovascular
diseases. In the general population, it is well reported that
overweight and obesity are associated with poor survival
and increased all-cause mortality.1,2
The prognostic implication of obesity, however, is prob-
ably different in patients with end-stage renal disease
(ESRD) on dialysis, with whom there is increasing evidence
that a high body mass index (BMI) confers a survival
advantage, whereas a low BMI and weight loss are associ-
ated with increased mortality.3e8 The reason for this phe-
nomenon of “reverse epidemiology” is not well understood.
Several studies suggested that the protective effect that is
observed with a high BMI in the dialysis population is the
result of a higher muscle build rather than adipose tissue
mass.9,10 However, a recent study found no association be-
tween lean body mass (a surrogate measure of muscle mass)
and patients survival3, and it was proposed that a higher
body fat mass does per se confer a survival advantage to
dialysis patients, probably because adipose tissue could act
as an energy reserve during catabolic or inflammatory
stress. Nonetheless, it remains possible that the relation
between body weight and mortality may not be a linear one:
a mild degree of overweight could be advantageous, while
gross obesity may be associated with increased mortality.
Most of the published studies on the relation between
obesity and ESRD focus on hemodialysis patients. Data on
patients receiving peritoneal dialysis (PD) are relatively
scarce. Previous reports suggest that a considerable pro-
portion of PD patients had substantial weight gain and fat
mass accumulation after the initiation of PD.11e13 However,
the exact prevalence, risk factors, and long-term implica-
tions of body weight gain amongst new PD patients remain
incompletely elucidated.Patients and methods
Patient selection
This is a retrospective cohort study. We reviewed 643
consecutive Chinese ESRD patients started on PD in ourcenter from 1998 to 2007. Patients who died within 1 year
after starting PD, those who were converted to hemodial-
ysis or received kidney transplant within 1 year after
starting PD were excluded because the change in body
weight could not be determined.
Clinical data
Baseline demographics and clinical information were
recorded by chart review. Comorbid conditions, including
diabetes mellitus, ischemic heart disease, cerebrovascular
accident, peripheral vascular disease, immunological dis-
eases, liver diseases, chronic lung diseases, and underlying
malignancy were recorded. A modified Charlson’s comor-
bidity index, which was validated in PD patients, was used
to calculate a comorbidity score.14
Body weight at the time of initiation of PD and 1 year
later, both measured when the patients were clinically
euvolemic, were recorded. Edematous and hypovolemic
patients were not excluded but treated according to their
clinical need before body weight was measured. The
change in body weight over 1 year of dialysis was then
computed accordingly. The euvolemic body weight was
defined as the weight at which the patient was clinically
edema-free and below which undesirable clinical signs and
symptoms of hypovolemia occur (for example hypotension
and muscle cramp).15 Serum biochemistries, including
fasting plasma glucose, HbA1c, fasting lipid profile, hemo-
globin, and albumin levels at the time of initiation of PD
and 1 year later were also recorded.
Peritoneal transport test
Peritoneal equilibration test (PET) was performed around a
monthafter the initiation of PD therapy.Weused the standard
PETas described by Twardowski.16 Dialysate-to-plasma ratios
of creatinine (D/P) at 4 hours was calculated after correction
of glucose interference.17 Mass transfer area coefficients of
creatinine (MTAC) normalized for body surface area (BSA) was
calculated by the formula described by Krediet.18
Estimation of glucose load
The daily glucose absorption from PDwas calculated from the
infused dialysate volumes and glucose concentrations during
30 A.S.-M. Choy et al.the 24-hour time interval, as well as the dialysis effluent
glucose concentration, as described by Davies et al.19 The
product of the volume and the glucose concentration of the
infused dialysis solution was calculated. The difference be-
tween infused and drained glucose content represents the
amount of glucose being absorbed during PD.
Dialysis adequacy and nutritional status
Dialysis adequacywas determinedduring baseline assessment
and then yearly by 24-hour dialysate and urine collections.
Total weekly Kt/V was determined by standard methods.20
Residual glomerular filtration rate (GFR) was calculated as
the average of 24-hour urinary urea and creatinine clear-
ance.21 Nutritional status was represented by serum albumin
level, subjective global assessment (SGA), comprehensive
malnutritioneinflammation score (MIS), normalized protein
nitrogen appearance (NPNA), and percentage of fat-free
edema-free body mass (FEBM). For SGA, the 4-item 7-point
scoring system, which was validated in PD patients22, was
used. The calculation of MIS was described previously by
Kalantar-Zadeh.23 Briefly, MIS consists of four main parts and
10 components, all scores from 0 (normal) to 3 (very severe).
The total score ranges from 0 to 30. NPNAwas determined by
the Bergstrom’s formula.24 FEBM was measured by creatinine
kinetics according to the formula of Forbes and Brunining.25
Clinical follow up
In general, patients were followed every 8 weeks, or more
frequently if clinically indicated. During the follow-upTable 1 Demographics and baseline clinical data.
Bo
<0.5 0
No. of patients 114 94
Sex (M:F) 64:50 43
Age (y) 57.2  13.3 58
Body height (cm) 160.0  8.2 15
Body weight (kg)
Baseline 65.0  13.8 57
1 y 62.8  13.5 57
Blood pressure (mmHg)
Systolic 145  24 14
Diastolic 77  15 81
Renal diagnosis, no. of patients (%)
Diabetic nephropathy 40 (35.1) 25
Glomerulonephritis 34 (29.8) 23
HTN 11 (9.6) 12
Polycystic kidney 2 (1.8) 4 (
Obstructive uropathy 6 (5.3) 6 (
Others/unknown 21 (18.4) 24
Major comorbidity, no. of patients (%)
Diabetes 52 (45.6) 31
Ischemic heart disease 22 (19.3) 14
CVA 25 (21.9) 19
PVD 6 (5.3) 6 (
Charlson’s score 5.44  2.59 5.1
CVA Z cerebrovascular accident; HTN Z hypertensive nephrosclerosperiod, patient management was decided by individual
clinicians and was not affected by the study. Overall pa-
tient survival, technique survival, and peritonitis-free sur-
vival were determined. The survival status was censored on
June 30, 2013. Censoring events for patient survival
included transfer to long-term hemodialysis, kidney trans-
plant, recovery of renal function, loss to follow up, and
transfer to other dialysis centers. Death within 30 days of
switching to hemodialysis was considered death on PD.
Death, kidney transplantation, and permanent cessation of
PD were defined as technique failure. Kidney trans-
plantation was considered as an event for technique failure
because patients might have received priority organ allo-
cation if they had impending technique failure.
Statistical analysis
Statistical analysis was performed by the Statistical Pack-
age for Social Sciences (SPSS) for Windows software,
version 18.0 (SPSS Inc., Chicago, IL, USA). All data are
expressed as mean  SD unless otherwise specified. For
convenience of analysis, patients were divided into four
groups according to the body weight change: weight loss >
0.5 kg, weight change  0.5 kg, weight gain 0.5e3.0 kg, and
weight gain > 3.0 kg in 1 year. Comparisons and correla-
tions between parameters were performed using the Chi-
square test, Student t test, Spearman’s rank correlation
coefficient, or Pearson’s correlation coefficient as appro-
priate. The impact of body weight gain during the 1st year
of PD on the subsequent clinical outcomes, including
overall patient and technique survival, were explored bydy weight change in 1 y (kg) p
.5eþ0.5 > 0.5e3.0 > 3.0
127 109
:51 66:61 60:49 0.45
.6  12.8 59.7  13.1 57.8  12.8 0.55
8.3  9.0 159.1  8.0 160.2  8.2 0.57
.8  11.3 57.8  10.1 59.2  11.0 0.003
.8  11.3 59.5  10.2 64.9  11.2 0.025
7  23 148  21 141  20 0.73
 14 80  13 72  11 0.07
0.73
(26.6) 43 (33.9) 43 (39.4)
(24.5) 29 (22.8) 33 (30.3)
(12.8) 12 (9.4) 7 (6.4)
4.3) 5 (3.9) 3 (2.8)
6.4) 8 (6.3) 4 (3.7)
(25.5) 30 (23.6) 19 (17.4)
(33.0) 57 (44.9) 59 (54.1) 0.09
(15.0) 21 (16.5) 33 (30.3) 0.047
(20.2) 29 (22.8) 26 (23.9) 0.64
6.4) 5 (3.9) 10 (9.2) 0.37
3  2.30 5.63  2.34 5.80  2.73 0.14
is; PVD Z peripheral vascular disease.
Table 2 Biochemistry and dialysis adequacy.
Body weight change in 1 y (kg) p*
<0.5 0.5eþ0.5 > 0.5e3.0 > 3.0
No. of patients 114 94 127 109
Time Baseline 1 y Baseline 1 y Baseline 1 y Baseline 1 y
Glucose load (mmol/d)** 293.8  141.4 269.9  118.7 266.5  133.2 266.2  130.4 0.09
HbA1c (%)** 6.47  1.05 6.20  0.96 6.47  0.92 6.55  1.20 0.44
Fasting plasma glucose (mmol/L) 8.3  4.0 6.9  3.1 8.2  4.3 6.0  1.7 8.0  4.3 6.1  2.0 8.6  4.8 6.5  2.4 0.46
Lipid profile (mmol/L)
Total cholesterol 5.0  1.3 5.2  1.2 5.3  1.1 5.4  1.0 5.2  1.4 5.6  1.4 5.1  1.5 5.3  1.2 0.92
Total triglyceride 1.9  1.2 2.2  1.6 2.0  1.4 2.3  1.5 2.0  1.5 2.4  2.0 1.9  1.2 2.6  2.3 0.99
LDL cholesterol 2.8  1.1 2.9  0.9 2.9  0.9 3.1  0.9 2.9  1.2 3.2  1.1 2.9  1.3 3.0  1.1 0.63
HDL cholesterol 1.3  0.4 1.3  0.4 1.5  0.7 1.4  0.4 1.5  0.6 1.4  0.5 1.3  0.4 1.3  0.4 0.80
Hemoglobin (g/dL) 9.1  1.6 9.2  1.9 9.3  1.4 9.5  1.7 9.0  1.2 9.3  1.7 9.3  1.5 9.3  1.7 0.41
Serum albumin (g/L) 32.4  5.3 33.7  6.0 32.4  5.5 34.5  5.0 32.3  5.8 33.9  5.7 31.5  6.2 33.2  5.7 0.46
D/P at 4 h (DP4) 0.65  0.14 e 0.61  0.14 e 0.62  0.15 e 0.62  0.15 e 0.20
Kt/V 2.18  0.58 1.99  0.51 2.28  0.52 2.09  0.48 2.23  0.52 2.09  0.49 2.19  0.83 2.00  0.51 0.70
Residual GFR (mL/min/1.73 m2) 3.80  2.63 2.26  2.23 3.62  2.28 2.43  2.19 3.61  2.22 2.51  1.95 3.36  2.26 2.52  2.05 0.30
NPNA (g/kg/d) 1.12  0.31 1.13  0.27 1.11  0.25 1.13  0.23 1.12  0.23 1.16  0.26 1.15  0.30 1.15  0.25 0.65
FEBM (%) 42.2  13.6 49.5  14.1 42.9  10.2 49.2  12.7 43.4  11.5 49.3  12.2 42.7  9.9 47.9  12.6 0.15
SGA score 5.63  0.90 e 5.51  1.10 e 5.58  1.17 e 5.64  0.96 e 0.81
MIS 7.00  3.12 e 7.20  3.23 e 5.76  3.42 e 6.52  3.20 e 0.16
Peritonitis during 1st y of PD
Peritonitis-free, no. of patient (%) 84 (73.7) 74 (78.7) 115 (90.6) 95 (87.2%) 0.001
Severe peritonitis, no. of patient (%) 3 (2.6) 2 (2.1) 0 1 (0.9%) 0.14
Peritonitis rate (episode/y) 0.46 0.31 0.13 0.20 0.001
D/P Z dialysate-to-plasma creatinine ratio; FEBM Z fat-free edema free body mass; GFR Z glomerular filtration rate; HDL Z high density lipoprotein; LDL Z low density lipoprotein;
MIS Z malnutrition inflammation score; NPNA Z normalized protein nitrogen appearance; PD Z peritoneal dialysis; SGA Z subjective global assessment.
* Comparison of baseline values between groups.
** Average value during the study period.
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32 A.S.-M. Choy et al.the KaplaneMeier analysis and log rank test. A value of
p < 0.05 was taken as statistically significant. All proba-
bilities were two-tailed.
Results
We identified 643 new PD patients during the study period;
86 were excluded as they were not on PD 1 year later (36
died, 31 received kidney transplantation, 13 converted to
hemodialysis, 5 transferred to other centers, and 1 was lost
to follow up). Another 113 patients were excluded because
a reliable dry weight could not be obtained 1 year after PD
as clinical euvoluemic status could not be achieved. The
final analysis therefore consisted of 444 patients. Their
baseline clinical characteristics and biochemical profile,
categorized according to their body weight change, are
summarized in Tables 1 and 2, respectively.
Weight change after 1 year of PD
The mean body weight was 60.0  12.0 kg at the initiation
of dialysis. After 1 year of PD, 114 patients (25.7%) had
weight loss > 0.5 kg (32 had weight loss > 3.0 kg), 94
(21.2%) had weight changes within  0.5 kg, 127 (28.6%)
had weight gain 0.5e3.0 kg, and 109 (24.5%) had weight
gain > 3.0 kg. The mean weight changes after 1 year of PD
was 1.34  3.27 kg. The distribution of weight change after
1 year of PD is summarized in Figure 1.
The baseline demographics and clinical data were
compared between weight change groups and are summa-
rized in Tables 1 and 2. Briefly, peritonitis episodes were
inversely related to body weight gain. Patients without any
peritonitis episode during the 1st year of PD had signifi-
cantly more weight gain than those who had peritonitis
(1.58  3.17 vs. 0.16  3.56 kg, pZ 0.001), and the number
of peritonitis episode during the 1st year of PD had a modest
but significant inverse correlation with weight gain duringFigure 1 Distribution histogram of weight change after 1
year of peritoneal dialysis.this period (rZ 0.174, pZ 0.0002). However, there were
no statistically significant difference in sex, age, preexist-
ing diabetes, cerebrovascular accident, peripheral vascular
disease, Charlson’s comorbidity index, systolic, and dia-
stolic blood pressure in patients with different weight
change groups, although patients with weight gain > 3.0 kg
were more likely to have preexisting ischemic heart disease
than other groups (p Z 0.047). In addition, weight change
had a modest but statistically significant correlation with
changes in residual GFR (r Z 0.137, p Z 0.004) and FEBM
(rZ 0.094, pZ 0.048). However, we did not observe any
significant difference in glucose load, peritoneal transport
characteristics, baseline serum albumin, fasting plasma
glucose, HbA1c, lipid profile, dialysis adequacy, or residual
renal function, among different groups of body weight
change. Similarly, no significant correlation was observed
between weight changes and changes in fasting plasma
glucose, lipid profile, serum albumin, and NPNA.
Patient and technique survival
After determining the weight change within 1 year of PD,
the cohort of patients was followed for a total of 2,7044
patient-months. The average duration of follow up was
60.9  32.8 months. During the study period, there were
254 deaths. The causes of death were cardiovascular dis-
ease (90 patients), cerebrovascular disease (27 patients),
peritonitis (49 patients), nonperitonitis infections (38 pa-
tients), termination of dialysis (25 patients), cancer (10
patients), and other or unknown causes (15 patients).
Within the same period of time, 56 patients were converted
to long-term hemodialysis, 61 had renal transplantation, 16
were transferred to other centers, and one had recovered
renal function. The causes of death and technique failure
were compared between weight change groups and are
summarized in Table 3.
The KaplaneMeier plot of patient survival is shown in
Figure 2. The overall patient survival rates at 60 months
were 45.0%, 54.8%, 54.0%, and 52.9% for patient groups
with weight loss > 0.5 kg, weight change within 0.5 kg,
weight gain > 0.5e3.0 kg, and weight gain > 3 kg,
respectively. There was no statistically significant differ-
ence in patients survival between patient groups (log rank
test, p Z 0.213).
The KaplaneMeier plot of technique survival is shown in
Figure 3. The technique survival rates at 60 months were
28.1%, 40.3%, 40.8%, and 36.7% for patient groups with
weight loss > 0.5 kg, weight change within 0.5 kg, weight
gain > 0.5e3.0 kg, and weight gain > 3 kg, respectively.
There was a significant difference in technique survival
between patient groups with different weight change (log
rank test, p Z 0.030); patients with weight loss > 0.5 kg
had worse technique survival than the other groups.
Discussion
In the present study, we found that weight gain was com-
mon among Chinese patients during the 1st year of PD.
There was no significant correlation between weight
change after PD and preexisting diabetes, glucose load,
dialysis adequacy, baseline residual renal function, or
Table 3 Causes of death and technique failure.
Body weight change in 1 y (kg)
<0.5 0.5eþ0.5 > 0.5e3.0 > 3.0
No. of patients 114 94 127 109
Cause of death*
Vascular diseases
Cardiovascular disease 22 19 26 23
Cerebrovascular disease 7 7 8 5
Infections
Peritonitis 6 10 16 17
Nonperitonitis infection 14 9 8 7
Others
Termination of dialysis 3 7 8 7
Malignancy 3 5 1 1
Liver cirrhosis 1 0 0 0
Miscellaneous/unknown 2 3 6 3
All deaths 58 60 73 63
Conversion to hemodialysis 19 10 12 15
Kidney transplantation 19 13 16 13
Transferal to other centers 4 2 5 5
Loss to follow up 0 0 0 0
Recovery of renal function 0 0 0 1
* There is no significant difference in the distribution of the cause of death between groups (p Z 0.51).
Weight change after PD 33peritoneal transport status. However, weight loss is more
commonly observed in patients who had peritonitis during
the 1st year of PD.
The mechanism of weight gain or accumulation of fat
tissue in PD patients is not well understood. It is possible
that with the initiation of dialysis and alleviation of uremic
symptoms, patients’ appetite improves, which would result
in weight gain. In addition, absorption of glucose from PD
solution may be a contributing factor. It has been estimatedFigure 2 KaplaneMeier plot of patient survival. Patients are
classified according to the body weight change after 1 year of
peritoneal dialysis.that PD patients derive about 20% of the daily energy intake
from dialysate in, corresponding to a daily energy intake of
4e13 kcal/kg body weight.26 In the present study, however,
we did not find any correlation between dialysate glucose
absorption and the degree of weight gain.
Although obesity is usually considered as a cardiovas-
cular risk factor, body weight is the sum of muscle, pe-
ripheral and central (i.e., abdominal) adipose tissue mass,
and the latter component appears to be the main risk factorFigure 3 KaplaneMeier plot of technique survival. Patients
are classified according to the body weight change after 1 year
of peritoneal dialysis.
34 A.S.-M. Choy et al.of cardiovascular disease, whereas muscle and peripheral
adipose tissue appear to be protective. In the general
population, central obesity is strongly associated with
multiple cardiovascular risks factors, including hyperten-
sion, diabetes mellitus, and hyperlipidemia.27,28 In patients
with CKD the REGARDS study showed that after adjusting
for clinical covariates, there was a graded increase in
mortality risk across increasing waist circumference cate-
gories.29 In this study, each 1 cm increase in waist
circumference was associated with a 2% increased mortality
risk, while every 1 kg/m2 increase in BMI was paradoxically
associated with a 3% decreased mortality risk.29 Similarly,
the Calabria Registry of Dialysis and Transplantation
(CREDIT) study found that in dialysis patients, BMI was
associated inversely with decreased all-cause mortality,
whereas there was a direct and linear association between
waist circumference and mortality.30 In our study, the
weight gain could be due to an increase in either fat or
muscle mass, which could not be differentiated by clinical
examination. Being a retrospective study, we have no data
on the waist circumference or body composition (e.g., as
measured by bioimpedance spectroscopy) for these pa-
tients, which may help to dissect the effects of obesity and
nutritional status.
In this study, we observed that patients with preexisting
diabetes seemed to have more significant weight change
(both increase and decrease) than nondiabetic patients
(see Table 1). Although appears paradoxical, our result is in
line with the report of Stenvinkel et al11, who noted that
diabetic patients tended to gain more fat than nondiabetic
patients after dialysis, while there was a simultaneous
decrease in lean body mass among diabetic but not non-
diabetics patients. The exact reason for this bidirectional
change in body weight is unknown. It is possible that the
absorption of glucose from the dialysis fluid could lead to
the accumulation of fat but also suppression of appetite
and reduction in dietary protein intake. In addition, phys-
ical inactivity is particularly common amongst diabetic
patients, and could lead to progressive muscle wasting but
fat accumulation.
In the present study, we observed that new PD patients
with weight loss > 0.5 kg within 1 year had a significantly
worse technique survival (and a trend of worse patient
survival) as compared with patients with stable or
increasing body weight. Our result is in line with previous
studies, which observed that a high BMI was associated with
improved survival in dialysis patients, while weight loss was
associated with increased mortality.3e8
In theory, weight loss in PD patients may be the result of
catabolic conditions (for example, dialysis-related in-
fections and inadequate dialysis).31 In the present study,
we found that peritonitis is probably the most important
cause of weight loss in PD patients. However, we found no
significant difference in Kt/V or residual renal function
between patients who lost or gain weight after 1 year of PD,
and the decline in residual GFR over 1 year did not correlate
with the magnitude of body weight change. Peritonitis ep-
isodes could result in weight loss by a number of mecha-
nisms, including hypoalbuminemia secondary to peritoneal
protein loss, skeletal muscle breakdown due to systemic
inflammatory response, and anorexia due to antibiotic
treatment. It has been estimated that an average loss of10% of body weight occurs during episodes of persistent
peritonitis.32 However, the worse technique survival in the
group with weight loss may also possibly be explained by
the change in peritoneal membrane transport characteris-
tics due to peritonitis. Unfortunately, serial data on peri-
toneal transport were not available in our study, and
further studies are needed to test this hypothesis.
Our study has several limitations. Dry body weight is an
arbitrary status in dialysis patients. Recent evidence sug-
gests that asymptomatic fluid overload is highly prevalent
amongst stable Chinese PD patients who are clinically
euvolemic.33 Measurement of changes in body weight
cannot distinguish the change in fat mass, muscle mass, or
body fluid status. In the present study, the determination of
euvolemic state was based on physicians’ clinical assess-
ment. However, clinical assessment is often not consistent,
and edema may not be detectable until the interstitial fluid
volume is grossly increased. Due to the retrospective design
of our study, we did not measure the body composition of
our patients to determine the body compartment that
contributed to the weight change. Although our patients
were clinically euvolemic, bioimpedance spectroscopy
would give a more accurate measurement of fluid status to
ensure the patients do not have clinically occult fluid
overload.
More importantly, data on the progressive changes of
body weight after 1 year were not available. A two-time
point determination of weight changes, while applied over
a long survival period, may render the conclusion on the
impact of weight change over PD patient less, and a
continuous measurement of body weight changes may have
a better correlation with long-term survival. In addition, we
had only one single measurement of body weight at either
time point (baseline and 1 year after PD). Since the day-to-
day variation in body weight of PD patients is poorly defined
but potentially substantial, our approach may lead to
misclassification of body weight change categories for an
unknown proportion of the study participants.
In conclusion, our present study demonstrated that
weight gain is common among Chinese patients during the
1st year of PD. There is no obvious correlation between
weight gain and glucose load, dialysis adequacy, baseline
residual renal function, or peritoneal transport status.
Furthermore, weight gain within the 1st year of PD is not
associated with any adverse clinical outcome. However,
weight loss > 0.5 kg during the 1st year of PD is common
amongst PD patients who have peritonitis during this
period, and is associated with worse technique survival
subsequently. Further studies are needed to delineate the
independent effects of muscle mass, adipose tissue mass,
and fluid overload on the clinical outcome of PD patients.Conflicts of interest
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